Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

With a portfolio of brands, such as Allegra ... reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...

Sanofi first telegraphed plans for a potential consumer health separation last October ... the company is known for popular household brands like the allergy med Allegra, Icy Hot for muscle ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... With a portfolio of iconic brands, such as Allegra, Doliprane and Dulcolax ...

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... With a portfolio of iconic brands, such as Allegra ...

Sanofi and CD&R enter ... attachment to Opella’s brands, hence our decision to remain vested in its future. We will support Opella on its path to become an independent company, grounded in talented ...

Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands ... Sanofi, which said a year ago it was reviewing separation scenarios for its consumer ...

Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a ...